AR063018A1 - Moduladores de los receptores de la progesterona - Google Patents

Moduladores de los receptores de la progesterona

Info

Publication number
AR063018A1
AR063018A1 ARP070104267A ARP070104267A AR063018A1 AR 063018 A1 AR063018 A1 AR 063018A1 AR P070104267 A ARP070104267 A AR P070104267A AR P070104267 A ARP070104267 A AR P070104267A AR 063018 A1 AR063018 A1 AR 063018A1
Authority
AR
Argentina
Prior art keywords
progesterone receptors
receptors modulators
fluorodibenzo
oxazepin
pyrido
Prior art date
Application number
ARP070104267A
Other languages
English (en)
Inventor
J B M Rewinkel
Hemen Ibrahim
B J B Folmer
Ollero M L Ollero
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon Nv filed Critical Organon Nv
Publication of AR063018A1 publication Critical patent/AR063018A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente provee moduladores de los receptores de la progesterona, los cuales son compuestos de (cis)-8-fluorodibenzo[b,f]pirido[1,2-d]oxazepin-1-amina y los usos de ellos. Reivindicacion 1: Un compuesto de (cis)-8-fluorodibenzo[b,f]pirido[1,2- d]oxazepin-1-amina de acuerdo con la (formula 1) caracterizado porque R1 es (C1-4)alquilo, opcionalmente sustituido por uno o más átomos de halogeno; y R2 es seleccionado entre un grupo qeu consta de H, halogeno, (C1-6)alquilo y CN; y R3, R4 y R5 son cada uno independientemente H o F.
ARP070104267A 2006-09-27 2007-09-27 Moduladores de los receptores de la progesterona AR063018A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06121372 2006-09-27

Publications (1)

Publication Number Publication Date
AR063018A1 true AR063018A1 (es) 2008-12-23

Family

ID=37813577

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070104267A AR063018A1 (es) 2006-09-27 2007-09-27 Moduladores de los receptores de la progesterona

Country Status (28)

Country Link
EP (1) EP2066677B1 (es)
JP (1) JP2010504943A (es)
KR (1) KR20090064454A (es)
CN (1) CN101522689B (es)
AR (1) AR063018A1 (es)
AT (1) ATE478078T1 (es)
AU (1) AU2007302007B2 (es)
BR (1) BRPI0716830A2 (es)
CA (1) CA2664120A1 (es)
CL (1) CL2007002788A1 (es)
CO (1) CO6160325A2 (es)
CY (1) CY1110846T1 (es)
DE (1) DE602007008589D1 (es)
DK (1) DK2066677T3 (es)
ES (1) ES2349325T3 (es)
HK (1) HK1126767A1 (es)
HR (1) HRP20100526T1 (es)
IL (1) IL197365A0 (es)
MX (1) MX2009002804A (es)
NO (1) NO20091016L (es)
NZ (1) NZ575276A (es)
PE (1) PE20071451A1 (es)
PL (1) PL2066677T3 (es)
PT (1) PT2066677E (es)
RU (1) RU2009115643A (es)
SI (1) SI2066677T1 (es)
TW (1) TW200820975A (es)
WO (1) WO2008037746A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI297685B (en) 2002-04-04 2008-06-11 Organon Nv Non-steroidal progesterone receptor modulators
CN101200429B (zh) * 2006-12-13 2012-08-22 上海睿智化学研究有限公司 2-硝基-4,5-二卤代苯酚类和2-氨基-4,5-二卤代苯酚类及其盐及其合成方法
US8063037B2 (en) 2007-05-07 2011-11-22 N. V. Organon Progesterone receptor modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1395467A (zh) * 2000-09-07 2003-02-05 美国拜尔公司 用作孕酮受体结合剂的环和非环脒以及包含它们的药物组合物
TWI297685B (en) * 2002-04-04 2008-06-11 Organon Nv Non-steroidal progesterone receptor modulators

Also Published As

Publication number Publication date
CN101522689B (zh) 2012-01-11
RU2009115643A (ru) 2010-11-10
HRP20100526T1 (hr) 2010-11-30
ATE478078T1 (de) 2010-09-15
HK1126767A1 (en) 2009-09-11
DE602007008589D1 (de) 2010-09-30
PT2066677E (pt) 2010-11-10
AU2007302007B2 (en) 2012-02-02
AU2007302007A1 (en) 2008-04-03
CN101522689A (zh) 2009-09-02
PE20071451A1 (es) 2008-10-30
CL2007002788A1 (es) 2008-04-18
TW200820975A (en) 2008-05-16
ES2349325T3 (es) 2010-12-30
CO6160325A2 (es) 2010-05-20
PL2066677T3 (pl) 2011-02-28
KR20090064454A (ko) 2009-06-18
MX2009002804A (es) 2009-03-31
EP2066677B1 (en) 2010-08-18
JP2010504943A (ja) 2010-02-18
CY1110846T1 (el) 2015-06-10
CA2664120A1 (en) 2008-04-03
IL197365A0 (en) 2009-12-24
DK2066677T3 (da) 2010-11-08
BRPI0716830A2 (pt) 2013-11-05
EP2066677A1 (en) 2009-06-10
NZ575276A (en) 2011-07-29
SI2066677T1 (sl) 2010-12-31
WO2008037746A1 (en) 2008-04-03
NO20091016L (no) 2009-03-30

Similar Documents

Publication Publication Date Title
PE20130012A1 (es) Derivados de pirazol como inhibidores de jak
GT200500185A (es) Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
AR049388A1 (es) Heterociclos como inhibidores de aldosterona sintasa
DOP2007000018A (es) Moduladores de indol sulfonamida de receptores de progesterona
GT200500183A (es) Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
AR075084A1 (es) Metodo de preparacion de quinolinil -oxidifenil - ciclopropanodicarboxamidas e intermediarios correspondientes
TW200720266A (en) Benzodioxane and benzodioxolan derivatives and uses thereof
PE20070752A1 (es) Triazolopiridazinas como moduladores de quinasa
ATE429427T1 (de) Pyrimidinderivate als orexin-rezeptorantagonisten
PE20091561A1 (es) Compuestos inhibidores de raf y metodos para su uso
AR056560A1 (es) Pirrolopiridinonas como moduladores cb1
AR072016A1 (es) Derivados de isoxazol que funcionan como potenciadores de los receptores de glutamato
AR065280A1 (es) Agentes antiparasitarios
AR059905A1 (es) Pirrolidina-3-ilaminas n-substituidas como antagonistas del receptor histamina-3, composicion farmaceutica y proceso para preparar el compuesto
CO6300861A2 (es) Compuestos inhibidores de dipeptidil peptidasa iv metodos de preparacion de los mismos y composiciones farmaceuticas que los contienen como agentes activos
AR082111A1 (es) Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas
PE20141940A1 (es) Compuestos triciclicos, composiciones que los comprenden y usos de los mismos
EA201070804A1 (ru) (аза)индольное производное, замещенное по положению 5, содержащая его фармацевтическая композиция, промежуточные соединения и способ их получения
PE20141579A1 (es) Nuevos 2h-indazoles como antagonistas del receptor ep2
AR065583A1 (es) Compuestos macrociclicos y composicion farmaceutica
PE20141169A1 (es) Derivados de etinilo
PE20061362A1 (es) Derivados de tetrahidronaftalina, procedimientos para su preparacion y su uso como inhibidor de la inflamacion
PE20141527A1 (es) Derivados de 2-amino-3-(imidazol-2-il)-piridin-4-ona, preparacion de los mismos y su uso terapeutico de los mismos
AR056087A1 (es) Derivados de azetidina como antagonistas de receptores de neuroquina nk
AR063018A1 (es) Moduladores de los receptores de la progesterona

Legal Events

Date Code Title Description
FA Abandonment or withdrawal